fda warning compounded semaglutide safety 2024 2025 Have patients been harmed by unsafe drug compounding? – Partnership for Safe Medicines FDA restricts non-approved compounded GLP-1

Glucagon-like peptide-1 (GLP-1) is an incretin known for its anti-obesity effects, and several effective drugs targeting GLP-1 receptors (GLP-1Rs) have recently been developed to treat obesity

Baar and Langer explore what GLP1 weight loss means for exercise, tendons, aging, and realworld obesity treatment.

There is currently no evidence supporting the use of probiotics to alleviate gastrointestinal side effects from GLP-1 receptor agonists, and this approach sh...

These may include improvements in endothelial function, reduction in inflammation, and beneficial changes in lipid metabolism

Remedy Meds Review is a telemedicine evaluation platform connecting patients to GLP-1 providers